Hoffmann Hans-Heinrich, Schneider William M, Rice Charles M
Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.
Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.
Trends Immunol. 2015 Mar;36(3):124-38. doi: 10.1016/j.it.2015.01.004. Epub 2015 Feb 20.
Over half a century has passed since interferons (IFNs) were discovered and shown to inhibit virus infection in cultured cells. Since then, researchers have steadily brought to light the molecular details of IFN signaling, catalogued their pleiotropic effects on cells, and harnessed their therapeutic potential for a variety of maladies. While advances have been plentiful, several fundamental questions have yet to be answered and much complexity remains to be unraveled. We explore the current knowledge surrounding four main questions: are type I IFN subtypes differentially produced in response to distinct pathogens? How are IFN subtypes distinguished by cells? What are the mechanisms and consequences of viral antagonism? Lastly, how can the IFN response be harnessed to improve vaccine efficacy?
自干扰素(IFNs)被发现并证明能在培养细胞中抑制病毒感染以来,半个多世纪已经过去了。从那时起,研究人员不断揭示干扰素信号传导的分子细节,梳理它们对细胞的多效性作用,并利用它们对各种疾病的治疗潜力。虽然取得了丰硕的进展,但仍有几个基本问题尚未得到解答,许多复杂性还有待揭示。我们探讨围绕四个主要问题的现有知识:I型干扰素亚型是否会因不同病原体而产生差异?细胞如何区分干扰素亚型?病毒拮抗作用的机制和后果是什么?最后,如何利用干扰素反应来提高疫苗效力?